{
    "nctId": "NCT06068257",
    "briefTitle": "Tumor-Derived FGF19",
    "officialTitle": "Translational Utility of Tumor-Derived FGF19 in a Novel Blood-Based Endocrine Suppression Approach",
    "overallStatus": "RECRUITING",
    "conditions": "Colorectal Cancer, Breast Cancer, Healthy",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 210,
    "primaryOutcomeMeasure": "To Identify and test thresholds, specificity and sensitivity for FGF19, (and associated markers) for detection in human blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The study will enroll adult persons with breast cancer or colorectal cancer or no cancer (healthy controls) who are able to do a fasting blood draw.\n\n(Pregnant women may choose to be in the study. The study procedures do not pose a risk to the safety of the unborn child or the woman.)\n\nExclusion Criteria:\n\n* The study will not enroll persons who are unable or unwilling to provide informed consent.\n* Adults unable to consent, individuals who are not yet adults, and prisoners will be excluded from this study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}